A Comparison of Long-acting Injectable Medications for Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2016

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

haloperidol decanoate

haloperidol decanoate injections, 25-200 mg once a month

DRUG

paliperidone palmitate

Paliperidone palmitate injections, 39 mg - 234 mg once a month

Trial Locations (22)

10032

Research Foundation for Mental Hygiene, New York

14623

University of Rochester, Rochester

19104

Philadelphia VA Medical Center-116A, Philadelphia

21061

Clinical Insights, Inc., Glen Burnie

27509

John Umstead Hospital/Duke University, Butner

27705

Carolina Behavioral Care, Durham

30912

Medical College of Georgia, Augusta

33316

University of Miami School of Medicine, Miami

44141

Louis Stokes Cleveland VA Medical Center, Brecksville

48201

John D. Dingell VA Medical Center, Detroit

48915

Sparrow St. Lawrence Hospital, Michigan State University Psychiatry, Lansing

52242

University of Iowa Hospital, Iowa City

64128

Kansas City Veterans Affairs Medical Center, Kansas City

67207

Clinical Research Institute, Wichita

68131

Creighton University Dept. of Psychiatry, Omaha

75235

University of Texas Southwestern Medical Center, Dallas

78711

Central Texas Veterans Health Care System, Waco

94304

VA Palo Alto Heathcare Systems, Palo Alto

98493

VA Puget Sound Health Care System, Tacoma

99204

Frontier Institute, Spokane

06519

Yale University/Connecticut Mental Health Center, New Haven

27599-7160

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Duke University

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

lead

New York State Psychiatric Institute

OTHER